Actively Recruiting
Randomized Phase II Trial Comparing Modified Short-Course Radiotherapy Plus CAPOX and Tislelizumab Versus Long-Course Chemoradiotherapy Plus Tislelizumab in Locally Advanced Rectal Cancer
Led by Fujian Cancer Hospital · Updated on 2026-10-01
130
Participants Needed
3
Research Sites
3 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating the complete response rate of two radiotherapy approaches combined with chemotherapy and the immune drug tislelizumab for people with locally advanced rectal cancer. This phase II study compares a modified short-course radiotherapy plus CAPOX chemotherapy and tislelizumab against the traditional long-course chemoradiotherapy plus tislelizumab. The goal is to find the best radiotherapy strategy to improve tumor shrinkage and increase the chance of complete response, aiming to offer better organ preservation options for patients. Participants are assigned to one of two groups one receives modified short-course radiotherapy targeting the tumor and lymph nodes over 5 sessions, followed by four cycles of oxaliplatin, capecitabine, and tislelizumab every three weeks the other group receives long-course radiotherapy over 25 sessions with concurrent capecitabine during radiation days and three cycles of tislelizumab every three weeks. After treatment, efficacy and surgery are evaluated. During the study, participants undergo assessments to measure complete response up to three months after neoadjuvant therapy and for up to a year after enrollment. Researchers also monitor organ preservation rates, surgical complications within 30 days, quality of life before surgery and up to 12 months after, and adverse events up to six months post-treatment. Long-term outcomes including disease-free survival, local recurrence-free survival, and overall survival are tracked for three years. The total study duration extends until 2027, with careful safety monitoring throughout.
CONDITIONS
Brief Title
Short-Course RT Plus CAPOX and Tislelizumab vs Long-Course CRT Plus Tislelizumab for Locally Advanced Rectal Cancer
Research Team
J
Jinluan Li, MD
C
Chunkang Yang, MD
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here